Tandem Diabetes Care is a medical device manufacturer that develops automated insulin delivery systems for people with diabetes. The company manufactures and sells advanced insulin pumps, including the Tandem Mobi system and t:slim X2 pump, powered by Control-IQ+ technology. This proprietary predictive algorithm with AutoBolus represents the only technology of its kind on the market, automating insulin delivery to improve glucose control and simplify diabetes management.
Founded in 2006 and headquartered in San Diego, California, Tandem is a publicly traded company on Nasdaq. Their human-centered approach to design and development focuses on creating new possibilities for people living with insulin-dependent diabetes. The company integrates with continuous glucose monitoring systems from Dexcom and Abbott FreeStyle Libre to create comprehensive automated insulin dosing systems. Tandem's commitment extends beyond products to comprehensive support programs and services for healthcare providers and patients.